HCmed UK Limited, situated in Chichester, West Sussex, UK, is the first international expansion of HCmed. We are dedicated to assisting our pharmaceutical partners in the development of combination products in the initial stages of feasibility studies. Our well-established team of scientists possesses extensive knowledge and proficiency in the field of pre-approval safety & efficacy testing of inhalation medical devices. This includes expertise in aerosol characterization, analytical techniques, microbiology, and fulfilling the regulatory prerequisites for drug-nebulizer testing. 

HCmed’s headquarters and R&D center are located in Taipei City. The company was founded in 2014 by an experienced team of professionals with a vision to innovate respiratory therapies. Our versatile team covers R&D, business development, quality assurance, and regulatory functions to incorporate market, pharmaceutical, and regulatory requirements into the CDMO services offered to pharma partners. 

HCmed’s R&D center consists of experts across several fields, including aerosol science, electrical engineering, and mechanical engineering. The R&D center is also equipped with state-of-the-art aerosol science laboratory facilities, providing a wide range of testing and analytical services. 

HCmed’s GMP (Good Manufacturing Practice) compliant manufacturing facility dedicated to nebulizer systems was established in 2018. The facility is located in the Zhonghe District of New Taipei City. With a designed capacity focused on our mesh nebulizer platforms Pulmogine and AdheResp, the site has been accredited with the ISO 13485 certification for quality management of medical devices. 

Production Ready Intelligent Mesh System

With the advanced production system, our mesh nebulizer platforms are ready to fulfill the testing and clinical study supply needs from our pharmaceutical partners. The manufacturing of our devices for clinical studies is carried out at HCmed’s GMP compliant manufacturing facility.